Carbapenems are a class of β-lactam antibiotics with a broad spectrum of antibacterial activity. They have a structure that renders them highly resistant to most β-lactamases. Carbapenem antibiotics were originally developed from thienamycin, a naturally derived product of Streptomyces cattleya.
Carbapenems are one of the antibiotics of last resort for many bacterial infections, such as Escherichia coli (E. coli) and Klebsiella pneumoniae. Recently, alarm has been raised over the spread of drug resistance to carbapenem antibiotics among these coliforms, due to production of the New Delhi metallo-β-lactamase, NDM-1. There are currently no new antibiotics in the pipeline to combat bacteria resistant to carbapenems, and worldwide spread of the resistance gene is considered a potential nightmare scenario.
Other articles related to "carbapenem antibiotics":
... Due to their expanded spectra, the desire to avoid generation of resistance and the fact that, in general, they have poor oral bioavailability, they are administered intravenously in hospital settings for more serious infections ... However, research is underway to develop an effective oral carbapenem ...
Famous quotes containing the word antibiotics:
“Even diseases have lost their prestige, there arent so many of them left.... Think it over ... no more syphilis, no more clap, no more typhoid ... antibiotics have taken half the tragedy out of medicine.”
—Louis-Ferdinand Céline (18941961)